Fig. 4From: Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trialIL-17 F–expressing CD4+ T cells and brain volume changes in RRMS patients and HCs. Decreased percentage of IL-17 F–expressing CD4+ T cells from baseline to 6 months correlated with decreased whole brain volume from baseline to 6 months in RRMS patients treated with IFN β-1a SC tiw. HC healthy control; IFN interferon; IL interleukin; RRMS relapsing–remitting multiple sclerosis; SC subcutaneously; tiw three times weeklyBack to article page